D Jackson Coleman1, Winston Lee1, Stanley Chang1, Ronald H Silverman1, Harriet O Lloyd1, Suzanne Daly1, Stephen H Tsang1,2,3. 1. Department of Ophthalmology, Columbia University, New York, New York, USA. 2. Jonas Children's Vision Care and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University, New York, New York, USA. 3. Department of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Abstract
OBJECTIVE: To evaluate PDE5/6 inhibition with sildenafil to reduce choroidal ischemia and treat age-related macular degeneration. METHODS: Sildenafil was prescribed to treat participants with macular degenerations or macular dystrophies measured by spectral-domain optical coherence tomography, color fundus photography, enhanced depth imaging, and best-corrected visual acuity. RESULTS: No change in calcified drusen was noted. Vitelliform-type soft drusen were not substantially changed. A participant with Best vitelliform macular dystrophy had a significant improvement in vision as well as in photoreceptor and ellipsoid layers. CONCLUSIONS: Our research supports sildenafil as a safe treatment for age-related and vitelliform macular degenerations. Thickened Bruch's membrane reduces the beneficial effect of perfusion increase, but all eyes appear to benefit from PDE6. Notably, maintenance or improvement in the photoreceptor layer may be the most significant result of sildenafil and is consistent with PDE6 inhibition. Thus, sil-denafil treatment of macular degeneration offers significant potential for vision retention and recovery.
OBJECTIVE: To evaluate PDE5/6 inhibition with sildenafil to reduce choroidal ischemia and treat age-related macular degeneration. METHODS:Sildenafil was prescribed to treat participants with macular degenerations or macular dystrophies measured by spectral-domain optical coherence tomography, color fundus photography, enhanced depth imaging, and best-corrected visual acuity. RESULTS: No change in calcified drusen was noted. Vitelliform-type soft drusen were not substantially changed. A participant with Best vitelliform macular dystrophy had a significant improvement in vision as well as in photoreceptor and ellipsoid layers. CONCLUSIONS: Our research supports sildenafil as a safe treatment for age-related and vitelliform macular degenerations. Thickened Bruch's membrane reduces the beneficial effect of perfusion increase, but all eyes appear to benefit from PDE6. Notably, maintenance or improvement in the photoreceptor layer may be the most significant result of sildenafil and is consistent with PDE6 inhibition. Thus, sil-denafil treatment of macular degeneration offers significant potential for vision retention and recovery.
Authors: Bruce A Berkowitz; Robert H Podolsky; Karen Lins Childers; Aicha Saadane; Timothy S Kern; Robin Roberts; Hailey Olds; Joydip Joy; Collin Richards; Tilman Rosales; Michael Schneider; Brennan Schilling; Arthur Orchanian; Emma Graffice; Kenan Sinan; Haohua Qian; Lamis Harp Journal: PLoS One Date: 2021-03-04 Impact factor: 3.752
Authors: D Jackson Coleman; Winston Lee; Suzanne Daly; Mark P Breazzano; Janet Sparrow; Stephen H Tsang Journal: Am J Ophthalmol Case Rep Date: 2020-12-03
Authors: Ivan Lylyk; Carlos Bleise; Pedro N Lylyk; Nicolas Perez; Javier Lundquist; Esteban Scrivano; Anibal A Francone; Martin Charles; Tamara Zompa; Pedro Lylyk Journal: J Neurointerv Surg Date: 2022-01-05 Impact factor: 8.572